

# The Role of Whole Body Imaging & the Opportunity for Screening



H. Peter Soyer, MD, FACD  
Dermatology Research Centre,  
The University of Queensland Diamantina Institute  
&  
Dermatology Department, Princess Alexandra Hospital  
Brisbane, Australia

[p.soyer@uq.edu.au](mailto:p.soyer@uq.edu.au)

 @UQDRC



# Conflicts of Interest




e-derm-consult GmbH  
MoleMap Australia  
iDoc24  
MetaOptima Inc  
FotoFinder  
Canfield Scientific Inc



# The Clinical Challenge








Figure 2. SROC curves for the performance of the clinical diagnosis without dermoscopy (red line), dermoscopy by experts (black line), and dermoscopy by non-experts (blue line).

Kittler H et al. Diagnostic accuracy of dermoscopy. Lancet Oncology 2002; 3: 159



# The Clinical Challenge





# Reducing Unnecessary Biopsies

Copy to: STONNINGTON DAY SURGERY UNKNOWN (95089509)

Requested: 16/03/2017  
Collected: 17/03/2017 11:12 AEDT  
Received: 17/03/2017 11:12 AEDT

demis in which there is a dermal scar. There is no evidence of a melanocytic lesion or malignancy.

SPECIMEN 10. There is a lentiginous and nested increase in bland appearing melanocytes along the dermoepidermal junction. A few nests of bland melanocytes are also present in the papillary dermis. There is no evidence of malignancy in the lesion is clear of the margins.

SPECIMEN 11. There is a lentiginous and nested increase in bland appearing melanocytes along the dermoepidermal junction. Small numbers of lymphocytes and melanophages are present in the papillary dermis. There is no evidence of malignancy. The lesion appears clear of the margins.

SPECIMEN 12. There is a lentiginous and nested increase in bland appearing melanocytes along the dermoepidermal junction. Small numbers of lymphocytes and melanophages are present in the papillary dermis. There is no evidence of malignancy. The lesion appears clear of the margins.

SPECIMEN 13. There is a lentiginous and nested increase in bland appearing melanocytes along the dermoepidermal junction. Small numbers of lymphocytes and melanophages are present in the papillary dermis. There is no evidence of malignancy. The lesion appears clear of the margins.

SPECIMEN 14. There is focal elongation of the rete ridges with basal hyperpigmentation and a lentiginous and nested increase in bland appearing melanocytes along the dermoepidermal junction. An adjacent cellular dermal scar is also seen. There is no evidence of malignancy. The melanocytic lesion appears clear of the margins.

SPECIMEN 15. Bland appearing melanocytes are present in the dermis. There is no evidence of malignancy. The lesion appears clear the margins.

SPECIMEN 16. Bland appearing melanocytes are present in the dermis. There is no evidence of malignancy. The lesion appears clear of the margins.

SPECIMEN 17. Bland appearing melanocytes are present in the dermis. There is no evidence of malignancy. The lesion appears clear of the margins.

SPECIMEN 18. There is a lentiginous and nested increase in bland appearing melanocytes along the dermoepidermal junction. A few nests of bland melanocytes are also present in the papillary dermis. There is no evidence of malignancy in the lesion is clear of the margins.

**CONCLUSION.**  
SPECIMEN 1. NO. 1 – BENIGN INTRADERMAL MELANOCYTIC NAEVUS.  
SPECIMEN 2. NO. 2 – BENIGN COMPOUND MELANOCYTIC NAEVUS.  
SPECIMEN 3. NO. 3 - BENIGN LENTIGINOUS COMPOUND MELANOCYTIC NAEVUS.  
SPECIMEN 4. NO. 4 – BENIGN COMPOUND MELANOCYTIC NAEVUS.

Sonic Dx Page 2 of 4

Copy to: STONNINGTON DAY SURGERY UNKNOWN (95089509)

Requested: 16/03/2017  
Collected: 17/03/2017 11:12 AEDT  
Received: 17/03/2017 11:12 AEDT

SPECIMEN 5. NO. 5 – BENIGN COMPOUND MELANOCYTIC NAEVUS.  
SPECIMEN 6. NO. 6 – BENIGN LENTIGINOUS JUNCTIONAL MELANOCYTIC NAEVUS.  
SPECIMEN 7. NO. 7 – BENIGN LENTIGINOUS JUNCTIONAL MELANOCYTIC NAEVUS.  
SPECIMEN 8. NO. 8 – BENIGN COMPOUND MELANOCYTIC NAEVUS.  
SPECIMEN 9. NO. 9 – UPPER DERMAL SCAR.  
SPECIMEN 10. NO. 10 – BENIGN LENTIGINOUS COMPOUND MELANOCYTIC NAEVUS.  
SPECIMEN 11. NO. 11 – BENIGN LENTIGINOUS JUNCTIONAL MELANOCYTIC NAEVUS.  
SPECIMEN 12. NO. 12 – BENIGN LENTIGINOUS JUNCTIONAL MELANOCYTIC NAEVUS.  
SPECIMEN 13. NO. 13 – BENIGN LENTIGINOUS JUNCTIONAL MELANOCYTIC NAEVUS.  
SPECIMEN 14. NO. 14 – BENIGN LENTIGINOUS JUNCTIONAL MELANOCYTIC NAEVUS AND ADJACENT DERMAL SCAR.  
SPECIMEN 15. NO. 15 – BENIGN INTRADERMAL MELANOCYTIC NAEVUS.  
SPECIMEN 16. NO. 16 – BENIGN INTRADERMAL MELANOCYTIC NAEVUS.  
SPECIMEN 17. NO. 17 – BENIGN INTRADERMAL MELANOCYTIC NAEVUS.  
SPECIMEN 18. NO. 18 – BENIGN LENTIGINOUS COMPOUND MELANOCYTIC NAEVUS.





# Reducing Unnecessary Biopsies

## Participant case study:

57 year old male with dysplastic naevus syndrome

Previous diagnoses of a Level 2 melanoma in 2015 and a Level 1 melanoma in March 2018

GP recommended excision of circled naevi in Juli 2018, diagnosed as two Level 1 melanomas

June 2018



September 2018 (3 months)




December 2018 (6 months)







# Patient Feedback





# Reducing Unnecessary Biopsies

## Participant case study:

57 year old male with dysplastic naevus syndrome

Previous diagnoses of a Level 2 melanoma in 2015 and a Level 1 melanoma in March 2018

GP recommended excision of circled naevi in Juli 2018, diagnosed as two Level 1 melanomas

June 2018



September 2018 (3 months)




December 2018 (6 months)





# Imaging Solutions: Dermoscopy



Non-invasive in vivo imaging technique with 10X magnification & illumination

Skin covered with a transparent medium or a polarised filter to minimise skin surface reflectance

Soyer HP et al. Early diagnosis of malignant melanoma by surface microscopy. [Letter to the Editor] Lancet 1987; 2: 803





# Imaging Solutions: Total-Body Photography

August 1988

## Total-Body Photographs of Dysplastic Nevi

William Slue; Alfred W. Kopf, MD; Jason K. Rivers, MD, FRCPC

*Archives of Dermatology* 124.8 (1988): 1239-1243.

First article describing the use of total-body photography to image naevi.



Fig 1.—At left is Nikon camera fitted with motor drive and 55-mm macro lens. This unit is used for 23 of 24 photographs. At right are Micronikkor (Nikon) 105-mm lens and Pn11 extension tube that are used for photographing the 1:1 image.




Fig 2.—Illustrations of different views taken for total-body photographs. Sites photographed are bound by dotted lines or solid-line rectangles. Top, On anterior and posterior surfaces of body, all demarcated areas (shaded and unshaded) are photographed. Bottom, On lateral aspects of body, only shaded areas are photographed.



# Imaging Solutions: Total-Body Photography



**1: Images of melanoma**

(a) View of posterior thighs of a patient at initial visit (baseline photograph).

(b) View of posterior thighs at review visit two years later, showing enlargement and darkening of a pigmented lesion on the right upper medial leg (arrow). Histopathological examination of this lesion showed level II superficial spreading melanoma, measuring 0.49 mm in maximum tumour thickness and arising in a preexisting dysplastic compound naevus.

(c) Macroscopic view of the changing lesion.

(d) Skin surface microscopy (epiluminescence microscopy) of the lesion.



A high incidence of melanoma found in patients with multiple dysplastic naevi by photographic surveillance




John W Kelly MD BS, FACD, Josephine M Yeatman MB BS, GradDipEpi, Cheryl Regalia, Grahame Mason MB BS, FRCPA, Amanda P Henham BAppSci(Photog), SRN

*Medical Journal of Australia* 167.4 (1997): 191-194.

First article using photographic surveillance to monitor changes in naevi (two year follow-up).  
Now adopted into various surveillance services for melanoma worldwide.



# Imaging Solutions: MoleMap





Health service model for melanoma surveillance

- 250,000+ patients (NZ, Australia) have chosen MoleMap
- 5 million+ moles checked
- 30+ clinics around Australia
- Whole-body approach to patient imaging



# Imaging Solutions: Fotofinder




FotoFinder ATBM  
(Automated Total-Body Mapping)

Offers consistent and automatic whole body documentation including:

- Mole mapping
- Psoriasis + computer-assisted PASI assessment
- Vitiligo
- Inflammatory skin conditions



# Imaging Solutions: Canfield Scientific



## Canfield's Vectra WB360 Imaging System

- Captures nearly the entire skin surface in a 3D image
- Macroquality resolution
- Imaging takes a few seconds
- Lesions can be annotated between timepoints with dermoscopy
- Captures details of both pigmented lesions and inflammatory skin conditions (e.g. psoriasis, vitiligo)





# Imaging Solutions: 3D Imaging in Clinics

## Clinical Perspective of 3D Total Body Photography for Early Detection and Screening of Melanoma

Jenna E. Rayner<sup>1,2</sup>, Antonia M. Laino<sup>1,2</sup>, Kaitlin L. Nufer<sup>1</sup>, Laura Adams<sup>1</sup>, Anthony P Raphael<sup>1</sup>, Scott W Menzies<sup>3,4</sup> and H. Peter Soyer<sup>1,2\*</sup>

Front Med (Lausanne) 2018 May 23;5:152.

First article establishing the use of 3D total body photography to improve early melanoma detection.





# Imaging Solutions: 2D vs 3D Photography



- Time consuming.
- Requires multiple separate images of the patient to be taken in a variety of anatomical positions.
- Manipulation of a 3D surface into a 2D photograph can compromise the accuracy of the image.

- Rapid acquisition.
- Single anatomical pose.
- Image in 3D, more closely reflecting clinical exam.
- Accurate spatial representation of body and naevi.



AUSTRALIAN  
CANCER  
RESEARCH  
FOUNDATION



2018 Grant Application for the ACRF ACEMID

ACRF **A**USTRALIAN **C**ENTRE OF **E**XCELLENCE IN  
**M**elanoma **I**maging & **D**iagnosis





## Executive Committee



**Prof H. Peter Soyer**  
Project & QLD Lead  
The University of Queensland



**Prof Graham Mann**  
NSW Lead  
The University of Sydney



**Dr Victoria Mar**  
VIC Lead  
Monash University

## ACRF ACEMID Research Programs



**Prof Monika Janda**  
Research Program Committee Lead  
The University of Queensland

## Diagnostic Intelligence



**A/Prof Pascale Guitera**  
The University of Sydney



**Prof Pablo Fernandez Penas**  
The University of Sydney



**A/Prof Chris McCormack**  
Peter MacCallum  
Cancer Centre



**Prof Richard Scolyer**  
The University of Sydney



**Prof Scott Menzies**  
The University of Sydney

## Clinical & Health Service Evaluation



**Prof Joanne Aitken**  
Cancer Council  
Queensland



**A/Prof Anne Cust**  
The University of Sydney



**A/Prof Rachael Morton**  
The University of Sydney

## Informatics



**Prof Len Gray**  
The University of Queensland



**Dr Liam Caffery**  
The University of Queensland




**Prof Rory Wolfe**  
Monash University





# Team Capability





# Health Service Partners


Cash-support: \$2,290,000  
In-kind support: \$6,332,522

## QUEENSLAND



**Sunshine Coast**  
Hospital and Health Service  
Exceptional people. Exceptional healthcare.

## VICTORIA



## NEW SOUTH WALES






## ADDITIONAL PARTNERS






# Research & Clinical Network



- 3,000 visits / instrument / year.
- 100,000 3D avatars and >5M naevi over the next 3 years.
- 50% with 1 and 2 year follow-up imaging.



The world's largest and most comprehensive skin imaging database



# Mission Statement

## Mission

**Transform melanoma early detection using total body surveillance to enhance individual lesion management**

## Research aims

**Diagnostic Intelligence**  
Improve early detection and risk stratification using total body images integrated with history, clinical phenotype and genotype.

**Health Service Evaluation**  
Total body imaging will reduce unnecessary biopsies by better 'hit' rate, improving cost for patients and the healthcare system.

**Informatics**  
Integrate total body imaging into a telehealth network and EMR through implementation of image standards.

## Critical infrastructure



ACRF funded telemedicine network of 15 total body imaging research nodes

## Outcomes

- World's largest, most comprehensive skin imaging database.
- Reliable solutions for melanoma early detection.
- Facilitate artificial intelligence.

- Research-validated ACRF infrastructure underpinning the first nationwide melanoma screening trial.









# Clinical Implementation



Images acquired at remote sites in DICOM format

Image stored in DICOM repository

Dermatologist reviews images using DICOM format




Referring or reporting clinician uses EMR to view images via enterprise image viewer



# Single Lesion vs Total Lesions Capture


One lesion, one time-point, limited meta-data



## Current status

- Lesion-focused analysis from individuals.
- Non-standard imaging.
- Limited / variable meta-data.
- No change.

All lesions, several time-points, comprehensive meta-data



## ACRF ACEMID capabilities

- Complete lesions assessment from all participants.
- Standardised and reproducible imaging.
- Extensive history, phenotype and genotype meta-data.
- Sequential imaging.



# Genetic Predisposition To Melanoma

**3 Melanomas**  
**87 Naevi**  
**Dark brown hair**  
**Brown eyes**  
**Fair skin**



**Heterozygote for albinism**

**Tyr**  
**PALB2**  
**LIG1**  
**MC1R r/r**

**2 Melanomas**  
**1 Naevi**  
**Light brown hair**  
**Blue eyes**  
**Fair skin**



**DNA repair defect**

**MC1R WT/r**  
**ATM**  
**RAD54L**  
**SETDB1**  
**POLG**





